Skip to main content
SpringerLink
Log in

„Therapeutic drug monitoring“ in Epileptologie und Psychiatrie

Therapeutic drug monitoring in epileptology and psychiatry

  • Übersichten
  • Published:
Der Nervenarzt Aims and scope Submit manuscript

Zusammenfassung

Bei einem Workshop am Epilepsiezentrum Bethel (02.12.2005) wurde von Referenten aus Epileptologie und Psychiatrie eine aktuelle Standortbestimmung des „therapeutic drug monitoring“ (TDM) bei Antiepileptika (AED) und Psychopharmaka vorgenommen. In der Epileptologie hat das TDM seit ca. 30 Jahren einen hohen Stellenwert, und auch für Psychopharmaka hat es sich etabliert. Für die Psychiatrie liegen mittlerweile Konsensusempfehlungen vor. Vor dem Hintergrund der Kostensituation im Gesundheitswesen steht TDM in der Diskussion zum einen im Hinblick auf die generelle Kosten-Nutzen-Relation und zum anderen im Hinblick auf eine mögliche Verlagerung in Großlabors. Für die Psychiatrie liegen Hinweise vor, dass sinnvoll eingesetztes TDM Kosten sparen kann, und für Psychiatrie und Epileptologie gilt, dass das Wissen und die Erfahrung von Speziallabors für zahlreiche Fragestellungen erforderlich sind. Möglichkeiten der wissenschaftlichen Auswertung von TDM-Daten werden diskutiert.

Summary

Experts from epileptology and psychiatry reviewed the current significance of therapeutic drug monitoring (TDM) of antiepileptic drugs and psychiatric drugs in a workshop at Bethel Epilepsy Centre in December 2005. TDM has been essential in epileptology for about 30 years, and it is also increasingly important in psychiatry, in which consensus recommendations were published recently. With regard to cost-cutting in the health system, there are discussions about the financial effect of TDM and outsourcing it to bigger laboratories. In psychiatry it has however been shown that sensibly used TDM may lead to reduced costs. Many issues in TDM require the knowledge and experience of specialised laboratories. The use of TDM data for scientific purposes was discussed at the workshop as well.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Aravagiri M, Teper Y, Marder SR (1999) Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20: 369–377

    Article  PubMed  CAS  Google Scholar 

  2. Baumann P, Eap CB (2002) Pharmacogenetics of chiral psychotropic drugs. In: Lerer B (ed) Pharmacogenetics of Psychotropic Drugs. Cambridge University Press, Cambridge, pp 181–214

  3. Baumann P, Hiemke C, Ulrich S et al. (2004) The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 37: 243–265

    Article  PubMed  CAS  Google Scholar 

  4. Baumann P, Kosel M, Voirol P (2000) Pharmakogenetische Charakterisierung – Pharmakogenetik in der Psychopharmakologie. In: Gastpar M, Banger M (Hrsg) Laboruntersuchungen in der psychiatrischen Routine. Georg Thieme Verlag, Stuttgart New York, S 134–149

  5. Bertilsson L, Dahl ML, Dalen P, Al Shurbaji A (2002) Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 53: 111–122

    Article  PubMed  CAS  Google Scholar 

  6. Bondolfi G, Eap CB, Bertschy G et al. (2002) The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients. Pharmacopsychiatry 35: 50–56

    Article  PubMed  CAS  Google Scholar 

  7. Brandt C, Pohlmann-Eden B (2006) Interaktionen zwischen Antiepileptika und Psychopharmaka. Z Epileptol 19: 95–108

    Article  Google Scholar 

  8. Clement Jerdi et al. (2004) J Pharmaceutical Biomed Analysis 35: 1203

  9. DeVane CL, Boulton DW, Miller LF, Miller RL (1999) Pharmacokinetics of trazodone and its major metabolite m-chlorophenylpiperazine in plasma and brain of rats. Int J Neuropsychopharmacol 2: 17–23

    Article  PubMed  CAS  Google Scholar 

  10. Dolder CR, Lacro JP, Dunn LB, Jeste DV (2002) Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 159: 103–108

    Article  PubMed  Google Scholar 

  11. El Ela AA, Hartter S, Schmitt U et al. (2004) Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds–implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 56: 967–975

    Article  CAS  Google Scholar 

  12. Fromm MF (2004) Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci 25: 423–429

    Article  PubMed  CAS  Google Scholar 

  13. Gaertner I, Gaertner HJ, Vonthein R, Dietz K (2001) Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. J Clin Psychopharmacol 21: 305–310

    Article  PubMed  CAS  Google Scholar 

  14. Gerloff T (2004) Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution. Naunyn Schmiedebergs Arch Pharmacol 369: 69–77

    Article  PubMed  CAS  Google Scholar 

  15. Glotzbach RK, Preskorn SH (1982) Brain concentrations of tricyclic antidepressants: single-dose kinetics and relationship to plasma concentrations in chronically dosed rats. Psychopharmacology (Berl) 78: 25–27

    Google Scholar 

  16. Hiemke C, Dragicevic A, Gründer G et al. (2004) Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 26: 156–160

    Article  PubMed  CAS  Google Scholar 

  17. Hiemke C, Baumann P, Laux G, Kuss H-J (2005) Therapeutisches Drug Monitoring in der Psychiatrie. Konsensus-Leitlinie der AGNP. Psychopharmakotherapie 12: 166–182

    Google Scholar 

  18. Hirsch LJ, Weintraub D, Du Y, Buchsbaum R et al. (2004) Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 63: 1022–1026

    PubMed  CAS  Google Scholar 

  19. Ingelman-Sundberg M (2001) Genetic susceptibility to adverse effects of drugs and environmental toxicants – The role of the CYP family of enzymes. Mutat Res 482: 11–19

    PubMed  CAS  Google Scholar 

  20. Jaquenoud Sirot E, Velden JW van der, Rentsch K et al. (2006) TDM and pharmacogenetic tests as tools in Pharmacovigilance. Drug Saf 29: 735–768

    Article  Google Scholar 

  21. Johannessen SI, Tomson T (2006) Pharmacokinetic variability of newer antiepileptic drugs: When is monitoring needed? Clin Pharmacokinet 45: 1061–1075

    Article  PubMed  CAS  Google Scholar 

  22. Kirchheiner J, Brøsen K, Dahl ML et al. (2001) CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 104: 173–192

    Article  PubMed  CAS  Google Scholar 

  23. Liston HL, Markowitz JS, DeVane CL (2001) Drug glucuronidation in clinical psychopharmacology. J Clin Psychopharmacol 21: 500–515

    Article  PubMed  CAS  Google Scholar 

  24. Lundmark J, Bengtsson F, Nordin C et al. (2000) Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 101: 354–359

    Article  PubMed  CAS  Google Scholar 

  25. Mann K, Hiemke C, Lotz J et al. (2007) Appropriateness of plasma level determinations for lithium and anticonvulsants in routine care of psychiatric inpatients with affective disorders. J Clin Psychopharmacol (submitted)

  26. Mann K, Hiemke C, Schmidt LG, Bates DW (2006) Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care. Ther Drug Monit 28: 83–88

    Article  PubMed  Google Scholar 

  27. Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75: 13–33

    Article  PubMed  CAS  Google Scholar 

  28. May TW, Rambeck B, Jürgens U (1999) Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit 21: 175–181

    Article  PubMed  CAS  Google Scholar 

  29. Meyer JH, Wilson AA, Sagrati S et al. (2004) Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 161: 826–835

    Article  PubMed  Google Scholar 

  30. Meyer UA (2000) Pharmacogenetics and adverse drug reactions. Lancet 356: 1667–1671

    Article  PubMed  CAS  Google Scholar 

  31. Preskorn SH, Fast GA (1991) Therapeutic drug monitoring for antidepressants: Efficacy, safety, and cost effectiveness. J Clin Psychiatry [Suppl 6] 52: 23–33

    Google Scholar 

  32. Rambeck B, Kurlemann G, Stodieck SR et al. (1997) Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child. Eur J Clin Pharmacol 51: 481–484

    Article  PubMed  CAS  Google Scholar 

  33. Reimers A, Skogvoll E, Sund JK, Spigset O (2005) Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol 25: 342–348

    Article  PubMed  CAS  Google Scholar 

  34. Rice DP (1999) The economic impact of schizophrenia. J Clin Psychiatry 60: 4–6

    PubMed  Google Scholar 

  35. Sabers A, Buchholt JM, Uldall P, Hansen EL (2001) Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 47: 151–154

    Article  PubMed  CAS  Google Scholar 

  36. Scordo MG, Spina E (2002) Cytochrome P450 polymorphisms and response to antipsychotic therapy. Pharmacogenomics 3: 201–218

    Article  PubMed  CAS  Google Scholar 

  37. Sidhu J, Job S, Singh S, Philipson R (2006) The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol 61: 191–199

    Article  PubMed  CAS  Google Scholar 

  38. Specht U, Elsner H, May TW et al. (2003) Postictal serum levels of antiepileptic drugs for detection of noncompliance. Epilepsy Behav 4: 487–495

    Article  PubMed  CAS  Google Scholar 

  39. Vuille F, Amey M, Baumann P (1991) Use of plasma level monitoring of antidepressants in clinical practice. Towards an analysis of clinical utility. Pharmacopsychiatry 24: 190–195

    PubMed  CAS  Google Scholar 

  40. Wolf P (1991) Antiepileptika haben keinen therapeutischen Bereich. Dtsch Med Wochenschr 116: 631–633

    Article  PubMed  CAS  Google Scholar 

  41. Wyatt RJ, Henter I, Leary MC, Taylor E (1991) An economic evaluation of schizophrenia. Soc Psychiatr Epidemiol 30: 196–205

    Google Scholar 

  42. Zernig G, Lechner T, Kramer-Reinstadler K et al. (2004) What the clinician still has to be reminded of. Ther Drug Monit 26: 582

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Evangelisches Krankenhaus, Epilepsiezentrum Bethel (Kliniken), Maraweg 21, 33617, Bielefeld, Deutschland

    C. Brandt & B. Pohlmann-Eden

  2. Département de Psychiatrie, Unité de Biochimie et Psychopharmacologie Clinique, Prilly-Lausanne, Schweiz

    P. Baumann

  3. Psychiatrische Klinik, Bezirkskrankenhaus, Kaufbeuren, Deutschland

    G. Eckermann

  4. Psychiatrische Universitätsklinik, Mainz, Deutschland

    C. Hiemke

  5. Pharmakologisches Labor der Gesellschaft für Epilepsieforschung e.V., Bielefeld, Deutschland

    T.W. May & B. Rambeck

Authors
  1. C. Brandt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Eckermann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Hiemke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T.W. May
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B. Rambeck
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. B. Pohlmann-Eden
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Brandt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brandt, C., Baumann, P., Eckermann, G. et al. „Therapeutic drug monitoring“ in Epileptologie und Psychiatrie. Nervenarzt 79, 167–174 (2008). https://doi.org/10.1007/s00115-007-2325-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00115-007-2325-x

Schlüsselwörter

Keywords

Search

Navigation